In order to solve this limitation, we consequently developed a new tumor-targeted delivery system for siRNAs, through their encapsulation into Fab′ fragments GD2-targeted coated CCLs, and validated their ability to silence the oncogene anaplastic lymphoma kinase (ALK) by increasing NB tumor binding and siRNA penetration-driven anti-tumor effect. The gene discussed is ALK; the disease is neoplasm.